Phase II Trial to Evaluate Benefit of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers and Mechanisms of Taxane Resistance in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Not Received Prior Chemotherapy
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Cabazitaxel (Primary) ; Docetaxel; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Biomarker; Therapeutic Use
- Acronyms TAXYNERGY
- Sponsors Sanofi
- 09 Oct 2018 Results published in the Clinical Cancer Research.
- 18 Feb 2017 Results of biomarker analysis, presented at the 2017 Genitourinary Cancers Symposium
- 26 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.